Showing results (241-250 of 262) with videos related to
Sort By:
Pageof 27
The British Journal of Dermatology|September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT studyR Dummer, A Guminksi, R Gutzmer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2017
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT studyJ T Lear, M R Migden, K D Lewis, et al.Oncogene|March 3, 2015
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapyE Lau, J Sedy, C Sander, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2020
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre studyM-C Brüggen, J Valencak, R Stranzenbach, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2014
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyD Schadendorf, M M Amonkar, M Milhem, et al.The British Journal of Dermatology|January 17, 2021
A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differencesC Dessinioti, A C Geller, A Stergiopoulou, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.Pageof 27